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Abstract 
 
Prospective randomized controlled trial of sinus grafting using 
Escherichia-coli-produced rhBMP-2 with a biphasic calcium 
phosphate carrier compared to deproteinized bovine bone 
 
Min-Soo Kim 
 
Department of Dentistry 
The Graduate School, Yonsei University 
(Directed by Professor Kyoo-Sung Cho) 
 
Aim: This study compared the effects of Escherichia-coli-produced recombinant 
human bone morphogenetic protein 2 (ErhBMP-2) with a biphasic calcium phosphate 
(BCP) carrier to those of deproteinized bovine bone in human maxillary sinus floor 
augmentation. 
 
Materials and Methods: Screening for this clinical trial selected 56 sites that 
provided informed consent to participate, of which 46 were ultimately enrolled and 41 
were finally included in the study. The sites were divided into two groups using a 
random-number table, and the material was applied. A trephine biopsy was performed 
after 24 weeks, and implants wider than the biopsy site were inserted. Computed 
tomography and plain panoramic images were obtained immediately and then again at 
v 
24 weeks after the surgery. Radiographic images were reconstructed to allow 
measurement of the linear and volumetric changes. The biopsy samples were 
processed for histologic and histometric analyses. 
 
Results: All sites healed uneventfully with no complications. Radiographic analysis 
revealed a tendency for the volume to increase, but the difference was not statistically 
significant in either group. Comparison of volumetric changes between the two 
groups also revealed no significant difference. Moreover, none of the histometric 
parameters differed significantly between the groups, although different healing 
patterns were observed on histologic analysis. 
 
Conclusion: It can be concluded that the efficacy of ErhBMP-2 with a BCP carrier is 
comparable to that of deproteinized bovine bone for maxillary sinus floor 
augmentation. ErhBMP-2 did not enhance bone regeneration compared to 
conventional grafting biomaterial at 24 weeks after sinus augmentation. 
 
 
 
 
                                                                         
Keywords: bone substitutes, clinical research, clinical trials, growth factors, sinus 
floor elevation  
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Escherichia-coli-produced rhBMP-2 with a biphasic calcium 
phosphate carrier compared to deproteinized bovine bones 
 
Min-Soo Kim, D.D.S., M.S.D. 
Department of Dental science 
Graduate School, Yonsei University 
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I. Introduction 
 
Since introduction of maxillary sinus augmentation by Boyne and James1, it has 
been the treatment of choice for restoration using dental implants in a maxillary 
posterior area showing a severely resorbed alveolar ridge or a pneumatized sinus2. 
Many previous clinical studies have demonstrated successful bone regeneration in the 
augmented sinuses, and comparable implant survival rates to those in the existing 
alveolar bone3-6. Mordenfeld et al.7 evaluated biopsy samples histologically at 11 
years after maxillary sinus augmentation using deproteinized bovine bone, and 
demonstrated the presence of mature regenerated bone tissue with unresorbed graft 
biomaterials.  
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Various graft biomaterials have been used for sinus augmentation for dental 
implant placement, such as autogenous, allogenic, and xenogenic bone, synthetic 
biomaterials, and a mixture of these biomaterials. The use of autogenous and 
allogenic bone is subject to limitations such as the morbidity at the donor site, 
insufficient quantity, and excessive resorption at the recipient site after a long period 
of healing8,9. Therefore, many clinicians prefer using space-maintainable biomaterials 
for sinus augmentation, such as hydroxyapatite (HA), biphasic calcium phosphate 
(BCP), or deproteinized bovine bone10-12. Because maxillary sinus is a contained 
defect surrounding osteogenic sources, the bony sinus floor and walls, and the 
Schneiderian membrane, successful bone regeneration and favorable clinical results 
can occur even in sinus augmentation using an osteoconductive biomaterial rather 
than an osteoinductive one. However, in cases of an extensive defect of the maxillary 
sinus, long healing periods will be needed for the production of bone that would be of 
clinically acceptable quality for implant placement6. 
To reduce the healing time for bone regeneration, recombinant human bone 
morphogenetic protein-2 (rhBMP-2) has been introduced and evaluated for used in 
various bone augmentation techniques in both the research and clinical fields. 
RhBMP-2 is a protein obtained from mammalian Chinese hamster ovarian cells, and 
was approved by the US FDA based on numerous clinical studies13-15. However, 
several recent in vitro and in vivo preclinical studies have demonstrated that 
Escherichia-coli-derived rhBMP-2 (ErhBMP-2) is comparable to rhBMPs derived 
from mammalian cells. Lee et al.16 found that when applied with an absorbable 
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collagen sponge (ACS) carrier, ErhBMP-2 induced significantly superior bone 
regeneration in a rat calvarial defect model compared with the control condition, over 
a wide range of doses. Jung et al.17 used an absorbable collagen block as a carrier for 
ErhBMP-2 to observe bone formation in the rat calvarial defect model, and confirmed 
the osteoinductivity of ErhBMP-2.  
The previous study also demonstrated enhancement osteoinductivity from 
Schneiderian membrane in vitro and in vivo experiments by ErhBMP-2, in which 
BCP was used as a scaffold due to its osteoconductivity and its ability to carry growth 
factors18. BCP with ErhBMP-2 has also exhibited favorable results in the rat calvarial 
model19. In addition, block-type BCP lyophilized with ErhBMP-2 was shown to 
enhance new bone formation20. Various preclinical studies involving animal 
experiments have confirmed the osteoinductivity of ErhBMP-2 with a BCP carrier 
(ErhBMP-2/BCP), whereas few clinical studies have applied ErhBMP-2 to defect 
models that include the sinus graft. Therefore, the present study used computed 
tomography (CT) and histologic analyses to compare the effects of ErhBMP-2/BCP 
with those of deproteinized bovine bone as a conventional standard of graft 
biomaterial in human maxillary sinus augmentation. 
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II. Materials and Methods 
 
This study was designed as a single-blinded, randomized, controlled clinical trial 
performed at two single-centers (Dental hospital of Yonsei university and Inha 
university hospital). The protocols used in this study were approved by the 
Institutional Review Board for Clinical Research at Yonsei Dental Hospital (approval 
no. 2-2011-0006), and observed the Helsinki Declaration (as revised in Tokyo in 
2004) and the Good Clinical Practice Guidelines. All of the included patients 
provided written informed consent to take part in the clinical experiments, and this 
manuscript was prepared according to CONSORT guidelines. 
 
 Sample size 1.
The sample size was calculated using G Power software (Version 3; Faul et al. 
2009)21. The null hypothesis was that ErhBMP-2/BCP has superior bone regeneration 
capacity relative to deproteinized bovine bone for sinus augmentation. The 
histometric difference in new bone area between two groups was assumed to be 10% 
with 90% power and an alpha level of 0.1. The standard deviation of the outcome was 
set to 10%, in accordance with22. The required sample size per group was 18 subjects, 
and 20 subjects were scheduled to be enrolled in each group in this study based on an 
assumed dropout rate of 10%. Among the 52 patients who volunteered to participate 
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in this study, 46 who conformed to the inclusion criteria were enrolled. The number 
of sites per institute was determined as followed based on the number of participating 
surgeons: 44 at Institute A and 12 at Institute B (Fig. 1). 
 
 Randomization 2.
Random group assignment was performed using block randomization (SAS, 
SAS Institute, Cary, NC, USA). Computer-generated random numbers were sealed in 
opaque envelopes by an independent person. After elevating the Schneiderian 
membrane, the envelope was opened and the corresponding assigned material was 
brought to the surgeon by an assistant. The enrolled patients were not informed of the 
assigned materials. 
 
 Preparation of ErhBMP-2/BCP particles 3.
An E. coli expression system was used to produce ErhBMP-2 at the research 
institute of Cowellmedi (Busan, Korea). Microporous BCP (particle type, 0.5–1.0 mm 
diameter, 70% porosity; Bio-C, Cowellmedi) consisting of HA and beta-tricalcium 
phosphate at a ratio of 30:70 was used as the carrier for ErhBMP-2. ErhBMP-2 was 
coated onto BCP particles using a previously described lyophilization method20. 
Briefly, ErhBMP-2 solution (0.67 ml in 1.5 mg/ml buffer) was added to 1 g of BCP 
particles and lyophilized in a freeze-dryer. The solution was frozen on shelves that 
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were precooled to –43°C. The formulations were dried in a condenser at –40°C 
(primary drying) and maintained at that temperature for 3 h, after which they were 
transferred to a pressure chamber at 5 millitorr for 2 h. Secondary drying was 
performed on a shelf using the following temperature sequence: –20°C for 4 h, –10°C 
for 4 h, 0°C for 2 h, and 20°C for 20 h. The pressure in the chamber was maintained 
constant throughout the procedure. 
 
 Timetable and surgical procedures 4.
Before the start of this trial, all researchers attended a calibration meeting at 
which an experienced senior surgeon (K.S.C.) described all steps of the surgical 
procedures to the participating surgeons. Antibiotics (500-mg amoxicillin or 150-mg 
roxithromycin) and analgesics (200-mg ibuprofen) were administered to all patients 1 
hour before and then for 7 days after surgery. Sinus floor augmentation was 
performed by a lateral-approach technique using a specially designed opening kit 
(LAS-KIT, Osstem, Seoul, Korea) and a membrane-elevation kit (DASK, Dentium, 
Seoul, Korea). A crestal incision and mesial vertical incision were made at the 
operation site with the patient under local anesthesia. A full-thickness mucoperiosteal 
flap was elevated to expose the alveolar crest and lateral wall of the maxillary sinus. 
A standard osteotomy was performed using a specially designed drill to make a round 
window in the bone (7 mm in diameter), and Schneiderian membrane was carefully 
elevated. According to random group allocation, the graft material—deproteinized 
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bovine bone (Bio-Oss, Geistlich Biomaterials, Wolhuser, Switzerland) for control 
group and prefabricated ErhBMP-2/BCP (Cowell BMP, Cowellmedi, Busan, 
Korea)—was packed into the space once continuity of the Schneiderian membrane 
had been confirmed. A Valsalva maneuver was applied to patients after grafting of 
the materials to again check that the Schneiderian membrane had not been perforated. 
After the material was grafted, the mucoperiosteal flap was sutured closed with 4-0 
glyconate absorbable monofilament (Monosyn, B-Braun, Aesculap, Center Valley, 
PA, USA), which was subsequently removed after 10–18 days. In order to acquire the 
initial parameters, postoperative radiographs were obtained immediately after 
completion of the sinus floor augmentation. 
Preoperative radiographs were obtained immediately before the implant 
surgery—which took place 24 weeks after the sinus floor augmentation—to evaluate 
the grafted site. Following elevation of the full-thickness flap, a biopsy sample of the 
grafted area was obtained carefully along the long axis of the planned implant site 
using a trephine bur with an internal diameter of 3 mm. One biopsy site per one 
grafted sinus was selected. Implants with a larger diameter than the biopsy 
preparation were inserted following a common surgical protocol. In cases of reduced 
bone quality, specific surgical methods such as undersized final drilling and 
osteotome sinus floor augmentation were performed to achieve primary stability. 
 
 
8 
 Radiographic analysis 5.
Various radiographs were obtained to evaluate the pathology, density, height, 
and width of the bone anatomy in the maxillary sinus. All acquired CT images were 
processed in DICOM format, and complete images that included the maxillary sinus 
area were analyzed using three-dimensional (3D) reconstruction software 
(OnDemand3D, CyberMed, Seoul, Korea). Sectional images acquired from the CT 
and plain panoramic radiographs were used to obtain the following linear 
measurement: the highest and lowest points of the grafted area (CT and plain images); 
the distance between the two points was calculated using a computer program. 
Volumetric changes were measured using polygonal cutting and color coding of the 
grafted area in reconstructed 3D images in each of three axes: coronal, sagittal, and 
axial. After processing, the volume of the isolated graft materials was measured 
automatically using a computer program (Fig. 2). The radiographic measurements 
were performed independently by two examiners (M.S.K. and H.K.S.). 
 
 Histologic analysis 6.
After the surgery, the trephined bony core that was removed at biopsy was 
carefully separated from the drills and decalcified in 5% formic acid over 14 days, 
and then embedded in paraffin. Serial coronal sections were cut along the center of 
each trephined specimen. The two central-most sections were chosen and stained 
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using hematoxylin and eosin and Masson’s trichrome. The histologic slides were 
observed under a light microscope (BX50, Olympus, Tokyo, Japan), and analyzed 
qualitatively. 
 
 Histometric analysis 7.
Histometric analysis was performed using an automated image-analysis system 
(Image-Pro Plus, Media Cybernetics, Silver Spring, MD, USA) by two independent 
examiners (M.S.K. and H.K.S.) to qualitatively evaluate the bone regeneration. The 
following parameters were evaluated: the area of residual graft material (RG), the 
area of newly formed bone (NB), and the nonmineralized area (NM). NM was 
calculated as the remaining area that was not RG or NB. 
 
 Statistical analysis 8.
The mean and standard deviation values of all parameters were calculated for 
both the experimental and control groups in the radiographic and histometric analyses. 
The paired and unpaired t-tests were used to determine the significance of any 
differences between time points and between the two groups, respectively (P=0.05). 
The interexaminer reliability for radiologic and histometric measurements was 
quantified using the interclass correlation coefficient (ICC). The ICCs were 0.869 and 
0.966 with a 95% confidence level in radiographic and histometric analyses, 
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respectively, which indicates a high level of reliability in the measurements made by 
the two examiners.   
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III. Results 
 
 Patient information 1.
Fifty-six volunteers (44 at Institute A and 12 at Institute B) applied to take part 
in this clinical experiment between July 2011 and October 2012. Ten volunteers were 
excluded between the screening and enrollment phases: six withdrew their agreement 
to participate before the surgery and four had a severely damaged Schneiderian 
membrane during the membrane elevation and were therefore unable to receive sinus 
floor augmentation. Thus, 46 sites were enrolled in this clinical study, and they were 
randomly divided into 2 groups: control (n=23) and experimental (n=23), with 34 and 
12 sites treated at Institutes A and B, respectively. Of these 46 sites, 5 were ultimately 
excluded after enrollment due to perforation of the Schneiderian membrane during the 
condensation of biomaterials in the elevated sinus (n=1), uncontrolled blood sugar 
levels (n=1), violation of the experimental schedule (n=1), and withdrawing their 
agreement to participate (n=2). This clinical trial was therefore completed with 41 
sites (22 males and 19 females aged 52.37±12.03 years, mean±SD) that underwent 
sinus floor augmentation and implant surgery. Thirty-one of the sites were treated at 
Institute A (16 and 15 in the control and experimental groups, respectively), and 10 
were treated at Institute B (5 in both groups; Table 1 and Fig. 1).  
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Table 1. Demographics of patient population and maxillary sinus 
 
 Experimental Control 
Distribution of Patients 
Age 52.70±13.55 51.95±10.80 
Male/Female 9/11 13/8 
Institute A/B 15/5 16/5 
Right/Left 12/8 9/12 
Distribution of Maxillary Sinuses 
Preexisting bone height 2.31±1.43 mm 1.74±0.72 mm 
Augmented height immediately after 
surgery 13.22±1.97 mm 12.67±2.47 mm 
Augmented height 24 weeks after 
surgery 14.51±3.27 mm 12,32±3.16 mm 
Mesio-distal dimension 34.72±6.28 mm 34.70±5.06 mm 
Bucco-palatal angle 70.80±14.99 mm 67.23±17.93 mm 
 
 Clinical findings 2.
All sites healed without major complications associated with the failure of sinus 
augmentation, including postoperative infection. However, specific clinical findings 
including minor complications presented in some subjects, comprising postoperative 
swelling, pain, and bleeding (n=7 and 1 for control and experimental group, 
respectively), perforation of the Schneiderian membrane (smaller than 3 mm in all 
cases) (n=4 and 3), separated two chambers in one maxillary sinus area by septum, 
which led preparation of two window openings (n=1 and 1), poor bone quality where 
the implant was installed (n=0 and 2), and the presence of protruding grafted particles 
to oral cavity postoperatively near the window opening (n=0 and 1). In cases with a 
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small perforation of the Schneiderian membrane, grafting biomaterials were applied 
after application of a collagen membrane (Bio-Gide, Geistlich Biomaterials, 
Wolhuser, Switzerland) at the perforated area. After 24 weeks the grafted sites 
remained stable prior to the implant surgery, and primary stability of all inserted 
implants was obtained in all subjects except for one in the experimental group, who 
experienced osseointegration failure. The mean follow-up period after delivery of the 
final restoration of the inserted implants was 94.83 days at Institute A and 203.67 
days at Institute B, and the cumulative survival rate of the total implants was 98.63%. 
 
 Radiographic findings 3.
Among the 41 sites, those with unusual scattering of the grafted material in the 
radiographs and in whom the proportional changes after 24 weeks exceeded 200% 
were regarded as having loss of continuity or breakdown of the Schneiderian 
membrane, and were excluded from the analysis (n=4). The height of the grafted area 
immediately after sinus floor augmentation was 13.41±4.27 mm in the experimental 
group and 13.86±3.59 mm in the control group on plain panoramic radiographs; after 
24 weeks these heights had changed to 13.66±4.75 mm and 14.17±4.19 mm, 
respectively. In sectional CT images, the initial height of the grafted area was 
12.55±3.27 mm in the experimental group and 13.11±2.03 mm in the control group; 
at 24 weeks after the sinus floor augmentation these heights were 13.29±3.44 mm and 
13.84±2.14 mm, respectively. Two different methods were used in the volumetric 
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analysis in order to reduce measurement errors: (1) using computer software to 
demarcate the augmented area based on the presence of radiopacity, with the acquired 
volume was directly applied as data, and (2) using the air volume in the maxillary 
sinus to calculate the difference between two time points. Since dental CT images that 
showed the whole maxillary sinus (especially the upper portion) were not available, 
two images from different time points of the same patient were superimposed to 
determine the reference points. The outlined maxillary sinus comprised radiolucent 
(air) and radiopaque (grafted materials) areas, and the changes in the augmented 
volume were calculated based on changes in the air volume (Fig. 2). Radiographic 
analysis revealed a slight tendency toward an increase in both linear and volumetric 
changes in both groups, but the difference was not statistically significant between the 
two time points in either group. Comparison of volumetric changes between the two 
groups also revealed no significant differences (Fig. 3 and 4). 
 
 Histologic findings 4.
Some differences in the healing pattern were observed on histologic analysis. In 
the experimental group, the surface of the BCP exhibited irregular morphology, 
possibly as a result of superficial resorption of the grafted material. Fatty marrow-like 
spaces were present between the RG and NB, especially in the experimental group. In 
contrast, the RG appeared to maintain its original morphology in the control group, 
even at 24 weeks after the surgery (Fig. 5 and 6). 
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 Histometric findings 5.
A region of interest was selected at most central area from the sinus floor to the 
uppermost point of the biopsy samples in all histologic sections. A biopsy was 
considered to have failed in subjects without native bone on the histologic slides, and 
was thus excluded from the histometric analysis. This resulted in three sites from the 
experimental group being excluded. The total areas were 10.27±5.56 mm2 and 
7.69±11.07 mm2 in the control and experimental groups, respectively. RG was 
distinguished based on the presence of specific morphology in both groups. In the 
control group, grafted particles had a similar morphology to the NB, but was 
characterized by sharp edges, trabecular patterns, and hollow lacunae without viable 
cells. The grafted material in both groups was surrounded by fibrous tissues and NB. 
NM mainly comprised fibrous tissue, fatty marrow-like adipose tissue, and blood 
vessels. The area of NB was 2.02±1.11 mm2 in the control group and 1.85±4.08 mm2 
in the experimental group; the corresponding RG areas were 1.79±1.24 mm2 and 
1.45±1.21 mm2, respectively, and those of NM were 6.45±3.80 mm2 and 4.39±6.23 
mm2. None of these parameters differed significantly between the two groups (Table 
2 and Fig. 7).  
All samples of both control and experimental groups were subcategorized to two 
types of sites, by whether small perforation of sinus membrane was occurred, to 
evaluate its effects as a confounding factor. These results were presented in Table 3. 
Although there were no differences in radiographically dimensional change or the 
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histologic proportion of newly formed bone, experimental sites with small perforation 
showed reduced area of newly formed bone (0.41±0.19 mm2) compared to other 
subcategorical groups (2.14±4.44, 3.39±1.17, and 2.05±1.13 mm2 for experimental 
site without perforation, and control sites with/without perforation, respectively). 
 
Table 2. Measurements of radiographic and histometric analyses 
 
  Control Experimental 
Radiographic analyses 
  Surgery 6 months Surgery 6 months 
Augmented height (2D) 12.89±3.76 12.75±2.97 13.70±3.32 14.51±4.11 
Augmented height (3D) 12.53±2.49 12.39±3.18 13.06±1.96 13.41±2.26 
Augmented volume 
(3D) 267.96±182.40 279.94±186.76 197.59±88.29 205.41±81.20 
Histometric analyses 
Newly formed bone 2.02±1.11 1.85±4.08 
Residual biomaterials 1.79±1.24 1.45±1.21 
Non-mineralized tissue 6.45±3.80 4.39±6.23 
Augmented height (mm) was measured in 2D (plain panoramic view) and 3D 
(reconstructed CT view), but augmented volume (mm2) was measured in 3D.   
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Table 3. Measurements of radiographic and histometric analyses in subcategorical 
groups according to the existence of membrane perforation during sinus augmentation. 
 
    Control Experimental 
Radiographic analyses 
    Surgery 6 months Surgery 6 months 
Augmented 
height (2D) 
Perfo. 14.72±2.30 13.63±3.60 14.82±3.80 13.57±3.68 
None 13.44±3.56 14.74±4.31 12.63±3.81 12.64±3.00 
Augmented 
height (3D) 
Perfo. 13.65±0.75 13.71±1.20 13.70±2.01 13.47±1.95 
None 12.88±2.19 13.31±2.54 12.31±2.56 12.20±3.36 
Augmented 
volume 
(3D) 
Perfo. 202.50±63.54 189.25±53.86 235.67±87.93 214.33±49.97 
None 288.11±203.67 307.85±205.42 189.43±89.43 203.50±87.79 
Histometric analyses 
Newly 
formed bone 
Perfo. 3.39±1.17 0.41±0.19 
None 2.05±1.13 2.14±4.44 
Residual 
biomaterials 
Perfo. 3.04±1.30 0.47±0.32 
None 1.83±1.26 1.65±1.23 
Non-
mineralized 
tissue 
Perfo. 6.38±6.25 1.94±2.21 
None 6.51±3.31 4.88±6.70 
Augmented height (mm) was measured in 2D (plain panoramic view) and 3D 
(reconstructed CT view), but augmented volume (mm2) was measured in 3D. 
 
Perfo.: subcategorical group with small sinus membrane perforation in both control 
and experimental group. 
 
None: subcategorical group without small sinus membrane perforation in both control 
and experimental group. 
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IV. Discussion 
 
This study aimed to quantify bone healing in a conventional sinus graft and in an 
alternative sinus graft that used ErhBMP-2, aided by radiographic and histologic 
analyses in humans, and was performed at two single-centers with a prospective, 
randomized, and single-blinded trial design. The authors hypothesized that ErhBMP-2 
would enhance bone regeneration in augmented maxillary sinus, based on previous 
preclinical studies showing acceleration of bone healing processes and ectopic bone 
formation in various experimental models. However, the results obtained in the 
present study failed to show any superiority of ErhBMP-2 in sinus augmentation at 24 
weeks after surgery relative to conventional sinus augmentation using the 
osteoconductive biomaterial. 
In radiographic analysis, dimensional changes were evaluated by comparing 
between the time immediately and 24 weeks after surgery, and the experimental and 
control groups showed similar patterns of volumetric and linear changes between two 
time points; there was a slight increase in the volume and height of the augmented 
area, with no significant differences between the two groups. However, the 
experimental sites that received ErhBMP-2/BCP showed wider ranges of height and 
volume changes after 24 weeks, with a higher maximum value for both the height and 
volume. These results are consistent with a previous study finding a significantly 
increased augmentation volume at sites that received ErhBMP-2/BCP compared to 
19 
BCP only in the early healing period in a rabbit sinus augmentation model18. That 
study found that the augmented volume was decreased at a later time period but still 
showed a slightly increased volume. ErhBMP-2 was found to increase postoperative 
tissue swelling or seroma during the early healing processes23-25, and this could affect 
the volumetric change. However, all specimens in both of the groups showed a 
clinically acceptable volume for dental implant placement and that this volume did 
not change significantly. 
All specimens analyzed histologically or histometrically in the present study 
showed evidence of new bone formation in the biopsy samples. Since these samples 
were taken at the site of a dental implant, histologic analyses were limited to within 
10 mm from the alveolar ridge crest regardless of the preexisting alveolar bone and 
augmentation height. The bone density and the proportion of residual biomaterials 
were comparable within these areas at the control and experimental sites. These 
results were in accordance with a previous preclinical study finding similar bone 
healing in the entire augmented sinus area in a rabbit sinus model at 8 weeks after 
surgery using the same biomaterials as those used in the present clinical study18.  
At the 2-week observational period, Choi et al.18 found a peculiar healing pattern 
at the sites treated with ErhBMP-2 but not at the control sites without ErhBMP-2. 
While newly formed bone was concentrated in the peripheral area around the 
Schneiderian membrane, limited bone tissue could be observed in the central area of 
the augmented sinus. Although the healing period was much longer in the present 
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clinical study (24 weeks) than in that previous preclinical study, this healing pattern 
could have affected the bone density in the central area of the augmented sinus, and 
hindered the acquisition of histologic biopsy samples. The use of a trephine drill 
resulted in smaller histologic specimens being taken despite using the same protocol 
at all sites (10.27±5.56 and 7.69±11.07 mm2 at the control and experimental sites, 
respectively). Interestingly, three experimental sites with small membrane perforation 
showed limited new bone tissue in histologic samples, while control sites with 
perforation showed comparable results to the other sites. This might be caused by 
healing mechanism that was dependent on the increase of osteoinductivity from 
Schneiderian membrane by ErhBMP-2, which had demonstrated in the previous 
animal study18. These results are consistent with a previous clinical study also finding 
that rhBMP-2 exerted negative effects on bone regeneration and density in sinus 
augmentation26. However, all of the other clinical, radiographic, and histologic 
parameters were indicative of comparable results in the control and experimental 
groups in the present study. Only one implant (in the experimental group) failed to 
acquire initial stability, and successful bone regeneration contacting with the residual 
biomaterial particles was evident in all of the acquired histologic samples. Therefore, 
like deproteinized bovine bone, ErhBMP-2/BCP can be used as a grafting biomaterial 
in sinus augmentation. 
The present clinical study was subject to some limitations in evaluating the 
separate effects of ErhBMP-2. To evaluate the effects of ErhBMP-2 on accelerating 
bone healing processes in sinus augmentation, biopsy and implantation should have 
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been performed earlier than when the final conventional clinical outcome occurs in 
order to compare the early phase of bone healing processes. However, the present 
clinical study was designed conservatively due to ethical issues, and this could have 
affected comparisons between the control and experimental groups. In addition, the 
scaffolding biomaterials differed between the two groups, with deproteinized bovine 
bone used at control sites as a conventional standard of graft biomaterial and BCP 
used at experimental sites, since this is the only biomaterial approved for use in 
conjunction with ErhBMP-2 in Korea according to domestic law. Therefore, the 
present results would be more conservative than those obtained in previous preclinical 
studies using the same biomaterials, and so further studies should be performed using 
various observational periods and scaffolding biomaterials.  
Within the limitations of this study, it can be concluded that the efficacy of 
ErhBMP-2 with a BCP carrier is comparable to that of deproteinized bovine bone for 
maxillary sinus floor augmentation in terms of clinical, radiographic, and histologic 
parameters. However, ErhBMP-2 did not enhance of bone regeneration compared to 
conventional grafting biomaterial at 24 weeks after sinus augmentation.   
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Figure Legends 
 
Figure 1. Randomization and treatment allocation chart. 
 
Figure 2. Radiographic analysis based on superimposition of computed tomographies 
immediately and 24 weeks after surgery. The augmented area could be observed on 3-
dimensionally reconstructed images (red arrowheads) at immediately (a) and 24 
weeks (b) after surgery, and these could be superimposed by unchangeable structures, 
like zygomatic arch, nasal septum, etc). After superimposition of reconstructed 
images, superimposed sectional images (d) can provide the dimensional changes from 
the time point immediately after surgery (c) and 24 weeks after the augmentation (e). 
Colorfully accentuated image: samples from 24-week observational period, dotted 
line: roof of the augmented area immediately after surgery. 
 
Figure 3. Representive radiographic views of control and experimental sites 
immediately and 24 weeks after sinus augmentation. (a) Control sites immediately 
after the surgery, (b) control sites after 24weeks from the surgery. (c) Experimental 
sites immediately after the surgery, (d) Experimental sites after 24weeks from the 
surgery. 
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Figure 4. Results of height and volume change between immediately and 24 weeks 
after sinus augmentation measured in radiographs. 
 
Figure 5. Representive histologic view of low magnification used as an region of 
interest (ROI) used in histomorphometric analysis. The lower border of the ROI 
corresponded to the lowest portion of the graft material, and the upper border 
corresponded to the highest portion of the trephined biopsy. (a) Control group; (b) 
experimental group (H-E; ×40). 
 
Figure 6. Representive histologic view of high magnification. (a) Histologic findings 
in the experimental group. The grafted particles were surrounded by NB as immature 
bony tissue. Nonmineralized tissues were composed mainly of fatty marrow-like 
tissue (FM) and there appeared to be adipose-tissue-rich zones. (b) A multinucleated 
cell (square box), assumed to be an osteoclast, was in contact with the grafted 
material in the experimental group. (c) Histologic findings in the control group. NB 
with many viable cells was observed between the grafted particles. The original 
morphology of the material was a cell-poor bony tissue [hematoxylin and eosin stain 
(H-E); ×100]. 
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Figure 7. Histometric analysis measured in region of interest. (NB = new bone, RG = 
residual graft, NM = non-mineralized area) 
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국문요약 
상악동 거상술에서 E. coli 유래 골형성 유도단백질 
결합 이상칼슘포스페이트와 탈단백 우골의 
골생성에 대한 전향적 임상 연구 
 
 <지도교수 조규성> 
 
연세대학교 대학원 치의학과 
김  민  수 
 
 
본 연구의 목적은 사람의 상악동 거상술시 이상 칼슘포스페이트와 
결합된 E-coli 를 이용하여 생산된 2 형 골형성유도단백질과 탈단백 우골을 
적용하였을 때의 효과를 비교하는 것이다. 
총 56 개의 상악동을 검사 하였으며 실험 참가 동의서와 술전 
주의사항 등을 전달 하였다. 46 개의 상악동을 선별 하였으며 최종적으로 
41 개의 상악동을 연구에 사용하였다. 난수표를 이용하여 대조군과 
실험군을 나눈뒤 시험이 진행되었으며 이식재 적용후 24 주에 관상톱 
생체검사와 동시에 검사부위보다 넓은 직경의 임플란트를 식립하였다. 
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전산화 단층 촬영과 파노라마 방사선 사진을 이용하여 이식재의 높이 
변화를 측정하였으며 3 차원적 재구성을 통해 부피의 변화도 측정하였다. 
생검 표본에 대해서는 조직학적, 조직계측학적 관찰을 시행하였다. 
모든 시험부위는 특이할 만한 합병증 없이 치유되었다. 방사선학적 
분석 결과 부피는 점진적인 증가 경향을 보였으나 통계학적인 유의성은 
없었으며 두 군간의 변화량 사이에도 통계학적인 유의성은 없었다. 또한 
조직학적 분석 결과, 치유 양상은 약간의 차이를 보였으나 조직계측학적 
결과에서는 두 군간에 유의할 만한 차이가 없었다. 
본 연구의 결과 이상 칼슘포스페이트 전달체 결합 골형성유도단백질은 
상악동 거상술시 탈단백 우골과 비교할 만한 효과를 보였다. 이는 이상 
칼슘포스페이트 전달체 결합 골형성유도단백질이 종전의 이식재인 탈단백 
우골과 비교했을 때 골재생을 향상시키지는 못했음을 보여준다. 
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